Summary: "The Management of NASH: What Does the Future Hold?"
1. Main Clinical Topics Discussed
- Epidemiology and updated prevalence data for NAFLD and NASH
- Non-invasive testing (NITs) strategies for risk stratification and fibrosis detection
- Diagnostic algorithms for primary care and specialist settings
- Current and emerging pharmacologic treatment landscape for NASH
- Management goals encompassing hepatic, metabolic, and cardiovascular outcomes
2. Key Learning Points, Guidelines, and Recommendations
Target Population for Pharmacologic Treatment:
- Not all NAFLD patients require pharmacotherapy
- Treatment targets "fibrotic NASH": NAFLD Activity Score (NAS) ≥4 plus significant fibrosis (F2–F3)
Non-Invasive Testing (NITs) — Serologic:
- FIB-4 Index (age, AST, ALT, platelet count):
- <1.3 → Low risk; manage in primary care
- 1.3–2.67 → Indeterminate; proceed to FibroScan
- >2.67 → High risk; refer to hepatologist
- Enhanced Liver Fibrosis (ELF) Test (hyaluronic acid, PIIINP, TIMP-1):
- <7.7 → No significant fibrosis (F0–F1)
- 7.7–9.8 → Indeterminate (~F2+)
- 9.8–11.3 → F3 fibrosis
- >11.3 → Cirrhosis
Non-Invasive Testing — Imaging:
- FibroScan (CAP score + transient elastography):
- CAP >275 dB/m → Significant steatosis
- LSM <6 kPa → No significant fibrosis; progressive cut-offs for F1–F4/cirrhosis
- LSM >8 kPa → Refer to specialist
- Advanced scores for hepatology settings:
- FAST Score (FibroScan + AST): >0.67 = at-risk NASH; <0.35 = low risk
- MAST Score (MRE + MRI-PDFF + AST): >0.242 = high risk; <0.165 = low risk
AGA Algorithm (2021):
- Sequential testing: FIB-4 → FibroScan
- Validated as practical triage tool for primary care
3. Specific Clinical Data and Study Results
Prevalence Study (San Antonio Cohort — Published in Journal of Hepatology):
- Middle-aged adults undergoing screening colonoscopy; no prior known liver disease
- MRI-PDFF used for steatosis quantification; liver biopsy for NASH diagnosis
- NAFLD prevalence: 38% (national average ~25–30%)
- NASH prevalence: 14% (prior general population estimates: ~5–6%)
High-Risk Subgroup Findings:
- Hispanic/Latino ethnicity: NAFLD 55%, NASH 25%
- Type 2 diabetes: NAFLD 70%, NASH 36%
- Hispanic + diabetic + obese: NAFLD ~92%, NASH ~50%
U.S. Population Impact (NHANES Database Analysis, ~10,000 FibroScans):
- Applied AGA algorithm to ~5,000 eligible subjects
- ~75% classified as low risk (50% by FIB-4 alone; additional 19% by FibroScan)
- Only 8% classified as high risk requiring hepatology referral
- Caveat: 12% of subjects with FIB-4 <1.3 had LSM >8 kPa on FibroScan, indicating potential missed advanced disease
Lifestyle Intervention Data (Weight Loss Pyramid):
- 3% body weight loss → Reduces steatosis
- ≥10% body weight loss → NASH resolution + fibrosis improvement
- Even in clinical trials, only ~10% of patients achieve the 10% weight loss threshold
Healthcare Capacity Gap: